Molecular oracles for multiple sclerosis therapy

被引：4

作者：

Wekerle, Hartmut ^{[1
]}

Hohlfeld, Reinhard ^{[1
]}

机构：

[1] Univ Munich, Max Planck Inst Neurobiol, Martinsried & Inst Clin Neuroimmunol, Munich, Germany

来源：

NATURE MEDICINE | 2010年 / 16卷 / 04期

关键词：

INTERFERON-BETA; DISEASE; CELLS;

D O I：

10.1038/nm0410-376

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Fewer than half of patients with multiple sclerosis respond to interferon-beta, one of the most widely prescribed therapies. The discovery that different subtypes of T cells may be involved in disease development in each affected individual suggests that it may be possible to predict therapeutic success by determining a patient's cytokine profile (pages 406-412).

引用

页码：376 / 377

页数：3

共 50 条

[31] Natalizumab Therapy of Multiple Sclerosis
Hutchinson, Michael
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2010, 30 (10): : 787 - 789
[32] Natalizumab Therapy for Multiple Sclerosis
Chataway, Jeremy
Miller, David H.
NEUROTHERAPEUTICS, 2013, 10 (01) : 19 - 28
[33] Daclizumab Therapy for Multiple Sclerosis
Bibiana Bielekova
Neurotherapeutics, 2013, 10 : 55 - 67
[34] Combination therapy in multiple sclerosis
Fernandez, Oscar
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2007, 259 (1-2) : 95 - 103
[35] Combined therapy in multiple sclerosis
García-Merino, JA
Blasco-Quítez, MR
Ortiz-Benítez, P
Puerta, C
REVISTA DE NEUROLOGIA, 2003, 36 (06) : 545 - 549
[36] Combination therapy in multiple sclerosis
Tullman M.J.
Lublin F.D.
Current Neurology and Neuroscience Reports, 2005, 5 (3) : 245 - 248
[37] The serum therapy of multiple sclerosis
Schottler, WHA
Selbach, H
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1944, 70 : 32 - 34
[38] Cell Therapy for Multiple Sclerosis
Tamir Ben-Hur
Neurotherapeutics, 2011, 8 : 625 - 642
[39] Symptomatic therapy in multiple sclerosis
Giovanni Luigi Mancardi
Neurological Sciences, 2006, 27 : s287 - s287
[40] Oral therapy for multiple sclerosis!
de Seze, J.
REVUE NEUROLOGIQUE, 2010, 166 (04) : 363 - 364

← 1 2 3 4 5 →